Men eftersom de farmakokinetiske data gav mulighed for at optimere dosis (så at den totale eksponering fra de to produkter var den samme), kan det konkluderes, at der foreligger en sammenhæng, der giver grundlag for, at den velunderbyggede anvendelse også anses for at gælde for Dolovet.
However, given that the pharmacokinetic data allowed to optimise the dose (keeping overall exposure comparable between the two products), it is concluded that a bridge exists that allows well- established use to apply to Dolovet.